Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc

NCT04189848 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04189848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
December 3, 2019
Completion date
February 27, 2020
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, healthy volunteers, obesity, overweight